Lung Cancer Europe (LCE) shared a post on X:
“A new 30-page review in Cell maps the state of ADCs (antibody-drug conjugates) – the ‘magic bullet‘ cancer therapy first imagined in 1907.
19 approved. 260 in development. SCLC: zero.
Non small cell lung cancer has genuine options now. But the review is direct about the gaps: patient selection, toxicity management, and tumors that are simply hard to reach.”
Title: Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
Authors: Louise Conilh, Virginia Metrangolo, Silvia Crescioli, Janice M. Reichert, Charles Dumontet
Other articles about Lung Cancer Europe (LCE) on OncoDaily.